ImmunityBio Q3 ANKTIVA Sales Jump 53% to $48.7M; Nine-Month Revenue Up 92%
IBRX has more than doubled off its 52-week low of $1.95.
Summary
ImmunityBio reported Q3 2026 net product revenue of $48.7 million, up 53% year-over-year, though the top line missed estimates, with first nine months revenue of $143.6 million, up 92%. The quarter's growth came entirely from ANKTIVA, which is now approved or authorized in six jurisdictions covering 35 countries, and the company recorded its first European sales in early Q4 plus an approval in Israel through partner Rafa Laboratories. The cost base is expanding fast: R&D rose to $71.5 million and SG&A to $54.0 million, pushing the GAAP net loss to $184.6 million versus $67.3 million a year ago, largely on non-cash fair value swings in the related-party convertible note and warrant liabilities, and the quarterly loss per share came in at 18 cents. Adjusted net loss, which strips those out, widened to $97.9 million from $72.4 million. Cash and marketable securities stood at $334.3 million at quarter-end, against a $1.75 billion total liability load that includes an $834.9 million related-party convertible note and a $426.3 million revenue interest liability. The BCG-naïve sBLA submission is targeted for this quarter, which is the next regulatory checkpoint for expanding the addressable population.
At the time of this announcement, IBRX was trading at $8.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $1.95 to $12.43. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.